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 14 
The response of cells to mechanical force is a major determinant of cell 15 
behavior and is an energetically costly event. How cells derive energy to resist 16 
mechanical force is unknown. Here, we show that application of force to E-17 
cadherin stimulates Liver Kinase B1 (LKB1) to activate AMP-activated protein 18 
kinase (AMPK), a master regulator of energy homeostasis. LKB1 recruits AMPK 19 
to the E-cadherin mechanotransduction complex, thereby stimulating actomyosin 20 
contractility, glucose uptake, and ATP production. The increase in ATP provides 21 
energy to reinforce the adhesion complex and actin cytoskeleton so the cell can 22 
resist physiological forces. Together, these findings reveal a paradigm for how 23 
mechanotransduction and metabolism are linked and provide a framework for 24 
understanding how diseases involving contractile and metabolic disturbances 25 
arise.   26 
 27 
In response to externally applied forces, cell surface adhesion receptors trigger 28 
robust actin cytoskeletal rearrangements and growth of the associated adhesion 29 
complex1-3. These changes are energetically costly, requiring approximately 50% of the 30 
total ATP in a cell4, 5. Energy homeostasis is controlled by AMP-activated protein kinase 31 
(AMPK). Based on this rationale, we tested whether application of force on E-cadherin 32 
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increased AMPK activity. For this, a well-established approach to directly apply force to 33 
cadherins was employed6-12. Magnetic beads were coated with E-cadherin extracellular 34 
domains (or IgG as a control) and permitted to adhere to MCF10A epithelial cells. A 35 
constant force was then applied for 5 minutes using a permanent ceramic magnet. 36 
Following application of force, AMPK was immunoprecipitated and subjected to an in 37 
vitro kinase assay with a fusion protein of GST and a SAMS peptide (an AMPK-specific 38 
substrate)13. Application of force increased phosphorylation of the SAMS peptide by 4.9-39 
fold; a control peptide (SAMA) lacking the second serine phosphorylation site was not 40 
phosphorylated (Fig. 1a). Importantly, the peptide phosphorylation was blocked by 41 
application of Compound C (a cell permeable AMPK specific inhibitor)14. 42 
 43 
As additional measures of AMPK activation, we examined phosphorylation of 44 
AMPK in its activation loop and phosphorylation of the AMPK substrate, acetyl CoA 45 
carboxylase. Force increased phosphorylation of AMPK in its activation loop in MCF10A 46 
(pAMPK, Fig. 1b) and MDCK (Fig. S1a) cells. The increases in activation loop 47 
phosphorylation were blocked when AMPK was inhibited using shRNAs (Fig. 1b) or 48 
Compound C (Fig. S1a-c). Phosphorylation of acetyl CoA carboxylase was also 49 
elevated (Fig. S1c). Hence by three independent measures, force stimulated AMPK 50 
activation.  51 
 52 
To ensure AMPK activation was independent of the method of force application 53 
shear stress was applied to MDCK cells using a parallel plate chamber. Alternatively, 54 
junctional assembly was triggered using a calcium switch assay—a process that relies 55 
on elevations in actin polymerization and myosin II activity15, 16. Both shear stress and 56 
junctional assembly stimulated AMPK activation loop phosphorylation (Fig. 1c,S1d). 57 
 58 
To interrogate the contribution of E-cadherin to force-induced AMPK activation, 59 
we examined the effects of inhibiting E-cadherin function using a function blocking 60 
antibody (HECD-1) or by silencing E-cadherin expression (Fig. 1d, S1e). E-cadherin 61 
was required to trigger AMPK activation (Fig. 1d, S1e). Additionally, application of force 62 
to another transmembrane adhesion receptor, syndecan-1, failed to enhance AMPK 63 
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phosphorylation (Fig. S1f). Taken together, these data demonstrate that force on E-64 
cadherin stimulates AMPK activation. 65 
 66 
To investigate the contribution of force to AMPK activation, we examined the 67 
effect of promoting and interfering with known mechanically controlled elements. To 68 
promote force transmission increases in contractility were stimulated by applying 69 
Calyculin A, a phosphatase inhibitor that augments myosin II phosphorylation. 70 
Stimulating myosin light chain phosphorylation increased AMPK activation (Fig. 1e). To 71 
interfere with force transmission, cells were treated with blebbistatin, a myosin II 72 
inhibitor. In the presence of blebbistatin, myosin light chain phosphorylation and force-73 
induced AMPK activation were decreased (Fig. 1d).  74 
 75 
Since activate AMPK localizes to the plasma membrane17 and E-cadherin is 76 
membrane-bound18, 19, we examined whether force stimulated AMPK recruitment to the 77 
cadherin adhesion complex. To address this possibility, we applied tensile forces to E-78 
cadherin and the level of co-precipitating AMPK and activated AMPK were assessed. 79 
AMPK (Fig 1f) and active AMPK (Fig 1g) were recovered with E-cadherin complexes. 80 
The recruitment of AMPK to E-cadherin was blocked by preincubation of the cells with 81 
blebbistatin (Fig 1f and g), with E-cadherin function blocking antibodies (Fig 1f and g), or 82 
by silencing AMPK expression (Fig S1g). Additionally, the recruitment of AMPK to E-83 
cadherin was not dependent on the method of force application as stimulating junctional 84 
assembly using a calcium switch assay triggered AMPK co-immunoprecipitation with E-85 
cadherin (Fig. S1h). Taken together, these studies demonstrate AMPK is recruited to E-86 
cadherin in response to force. 87 
 88 
How is AMPK activated and recruited to the cadherin complex? Previous studies 89 
from the Schwartz laboratory indicated that LKB1, an AMPK activator, localizes to 90 
cadherin-containing complexes in maturing junctions17. Additionally work from Cantley 91 
laboratory found that calcium-induced tight junction assembly depends on LKB120. 92 
Based on this rationale, we determined if LKB1 associates with  the cadherin adhesion 93 
complex in response to force. LKB1 was recovered with E-cadherin-coated magnetic 94 
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beads in a force- and E-cadherin-dependent manner (Fig 2a). Since the buffer 95 
conditions used to examine protein recruitment beneath the magnetic beads were less 96 
strigent than convention co-immunoprecipitation studies, we examined if LKB1 co-97 
immunoprecipitated with E-cadherin. Robust co-immunoprecipitation of E-cadherin was 98 
observed LKB1 immunoprecipitates recovered from cells lysed in a 1%-triton x100-99 
containing buffer, thereby confirming the interaction (Fig 2b). In further support of LKB1, 100 
we determined if LKB1 co-localized with E-cadherin in cells. Since the magnetic beads 101 
we use in these studies autofluorescence, we examined co-localization in response to 102 
application of shear stress to MDCK cells. We observed strong co-localization of LKB1 103 
and E-cadherin (Fig 2c).   104 
 105 
Having identified a mechanically-active signaling pathway from E-cadherin to 106 
LKB1, we next determined if LKB1 is required for AMPK activation and recruitment to 107 
the cadherin adhesion complex. Tensile forces were applied to E-cadherin on MCF10A 108 
(Fig 2d) or on MDCKII (Fig 2e) cells. We found the force-induced activation of AMPK 109 
was prevented by LKB1 silencing in both cell lines (Fig 2d-e). Similarly, shear stress-110 
induced activation of AMPK was blocked by inhibition of LKB1 (Fig 2f). We next 111 
determined whether LKB1 was required for the recruitment of AMPK to E-cadherin. 112 
LKB1 inhibition prevented co-precipitation of AMPK and active AMPK with E-cadherin 113 
coated magnetic beads (Fig 2g). Taken together, this data demonstrates that LKB1 is 114 
needed for AMPK to be recruited to and activated at cadherin-containing sites. 115 
 116 
The observation that LKB1 and AMPK are recruited to the cadherin adhesion 117 
complex suggests they may lie in a known contractility pathway. This pathway initiates 118 
when E-cadherin activates Abelson tyrosine kinase (Abl) thereby triggering 119 
phosphorylation of Y822 vinculin (Fig. 3a) and culminating in elevated RhoA-mediated 120 
contractility11. To determine whether LKB1 and/or AMPK are components of this 121 
pathway, we examined the effect of their inhibition. As an indicator of Abl activation, we 122 
followed phosphorylation the Abl substrate, CrkL, using a phosphospecific antibody 123 
against the Abl-specific sites21. Application of tensile forces using the magnetic bead 124 
approach stimulated CrkL phosphorylation in MCF10A (Fig 3b and c) and MDCKII cells 125 
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(Fig. S2a). Inhibition of LKB1 (Fig. 3b, S2a) or AMPK (Fig. 3c, S2b) prevented this 126 
increase. Stimulation of vinculin Y822 phosphorylation, a downstream target of Abl, also 127 
required LKB1 (Fig. 3d) and AMPK (Fig 3e, S2c). These data indicate that AMPK lies 128 
upstream of Abl in the known contractility pathway. Since Abl is activated and AMPK 129 
and vinculin are recruited to cadherin-containing junctions in response to force22, we 130 
examined whether AMPK is in a complex with these components. For this, we 131 
monitored co-immunoprecipitation of vinculin and Abl with AMPK from cells lysed in 132 
RIPA buffer. These studies revealed that AMPK forms a complex with Abl and vinculin 133 
in a force-dependent manner (Fig. 3f).     134 
 135 
Further downstream in the E-cadherin contractility pathway (Fig. 3a), RhoA-136 
mediates activation of Rho kinase, which promotes phosphorylation of myosin light 137 
chain (MLC), thereby stimulating actomyosin contractility23. We measured force-induced 138 
RhoA activity in cells in the presence or absence of LKB1 or AMPK. Application of 139 
tensile force to E-cadherin stimulated RhoA activation in an LKB1- and AMPK-140 
dependent manner (Fig. 3g). To determine if increases in RhoA were propagated to 141 
changes in contractility, we analyzed MLC phosphorylation at a regulatory Ser19 site24. 142 
MLC phosphorylation increased 2.7-fold in response to force (Fig 3h). Inhibition of 143 
AMPK or LKB1 abrogated these effects (Fig. 3g, 3h, S2d, and S2e). Taken together, 144 
these findings demonstrate that AMPK is required to increase RhoA-mediated 145 
contractility when E-cadherin experiences force.   146 
 147 
These observations raise the question why cells activate a master regulator of 148 
metabolism, such as AMPK, to modulate contractility. When cells experience force, 149 
elevations in enzymatic activity, actin polymerization, and actomyosin contractility 150 
facilitate the cytoskeletal rearrangements and the growth of adhesions necessary to 151 
withstand the force2, 25-28. All of these processes require energy. The preferred energy 152 
source for epithelial cells is ATP derived from glucose oxidation29. In other systems, 153 
AMPK activation stimulates glucose uptake and oxidation30. Based on this rationale, we 154 
hypothesized a consequence of force-induced AMPK is the stimulation of glucose 155 
uptake. To test this possibility, tensile forces were applied to E-cadherin and the uptake 156 
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of a fluorescently labelled, non-hydrolyzable 2-deoxyglucose was monitored. Force 157 
stimulated a 2.2-fold increase in glucose uptake in the MCF10A cells (Fig. 4a, Fig. S3a) 158 
and a 2.6-fold increase in the MDCK II cells (Fig. 4b, Fig. S3b). Moreover, inhibition of 159 
E-cadherin, LKB1, or AMPK prevented the force-induced glucose uptake (Fig. 4a-b, Fig. 160 
S3a-b). To ensure that these results were not the consequence of the approach, the 161 
effects of shear stress on MDCKII cells or the effects of stimulating junctional assembly 162 
(using a calcium switch assay) were monitored. Both methods stimulated an elevation in 163 
glucose uptake. The fold activation was similar to the increase observed when tensile 164 
forces applied (Fig. 4c, S3c, S3d) and required E-cadherin, LKB1 and AMPK. 165 
Collectively, these data demonstrate that force on E-cadherin stimulates glucose uptake 166 
in a LKB1- and AMPK-dependent manner. 167 
 168 
In response to many stimuli, glucose is oxidized to ATP. Hence, we tested 169 
whether increases in glucose uptake translate to elevations in ATP. Application of force 170 
to E-cadherin increased cellular ATP levels by 1.5-fold (Fig. 4d and S3e). The increase 171 
in ATP, while slight, was statistically significant and reproducible (Fig. S3e). This 172 
modest change is not surprising as ATP levels remain relatively constant, even in the 173 
most metabolically active tissues31. Importantly, we found force-induced ATP could be 174 
blocked by the shRNAs against LKB1 or AMPK (Fig 4d), the AMPK inhibitor Compound 175 
C (Fig. 4e, Fig S3f), or the ATP synthase inhibitor Oligomycin A (Fig. 4e, Fig S3f). To 176 
ensure that the ATP produced was derived from glucose, the effect of a non-177 
hydrolyzable, 2-deoxyglucose analog was studied. The 2-deoxyglucose analog blocked 178 
force-induced elevations in ATP (Fig. 4e). Taken together, these data indicate that the 179 
glucose taken up when E-cadherin experiences force is converted to ATP.  180 
  181 
 We next tested the possibility that ATP provides the energy necessary to 182 
reinforce the actin cytoskeleton and cadherin adhesion complex in response to force. In 183 
support of a role for AMPK, we found that A-769662, an AMPK activator, increased E-184 
cadherin and F-actin enrichment in cell-cell junctions (Fig. S4a). To directly test the role 185 
for LKB1 and AMPK, we applied shear stress to MCDK cells and monitored F-actin and 186 
E-cadherin enrichment in cell-cell junctions using immunofluorescence. A 2.0-fold 187 
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increase E-cadherin deposition in cell-cell junctions (Fig. 5a and b) and a 3.8-fold 188 
increase in junctional actin were observed in cells exposed to shear (Fig 5a and c). 189 
These increases were blocked by shRNAs against LKB1 or inhibitors of AMPK (Fig 5a-190 
c). Similarly, inhibiting glucose metabolism (by incubating cells in low glucose containing 191 
media) or blocking ATP synthesis (using Oligomycin A or Carbonyl cyanide-4-192 
(trifluoromethoxy)phenylhydrazone) dramatically impaired junctional enrichment of F-193 
actin and E-cadherin in shear stress treated cells (Fig. 5a-c). Only modest changes 194 
were observed in control cells (Fig. S4b-d).  195 
 196 
To ensure that shear stress applied force to cell-cell junctions, we investigated 197 
whether myosin light chain was phosphorylated in response to shear and whether 198 
vinculin (an actin binding protein that bears force) was enriched in cell-cell junctions. 199 
Both myosin light chain phosphorylation and vinculin localization to cell-cell contacts 200 
were increased in response to shear stress (Fig. S4e-h). In further support of a role for 201 
force, we found that the enrichment of vinculin in cell-cell junctions was blocked by 202 
preincubation of cells with blebbistatin (Fig. S4e-g). This observation is in agreement 203 
with previous findings showing vinculin is recruited to endothelial cell-cell junctions in a 204 
tension-dependent manner32 and force-dependent vinculin recruitment can be blocked 205 
by blebbistatin22. Collectively, these data demonstrate that AMPK-dependent increases 206 
in ATP enrich F-actin and E-cadherin in response to force.   207 
 208 
 Previous studies show that tension is required for the formation of an epithelial 209 
barrier33. To interrogate the physiological significance of the pathway uncovered in this 210 
study, the formation of an epithelial barrier was monitored in MDCKII cells after a 211 
calcium switch. After readdition of calcium to the medium, control cells gradually formed 212 
an epithelial barrier (Fig.  5d). Inhibition of E-cadherin, LKB1, or AMPK or Blebbistatin 213 
compromised formation of the barrier function. By 24 h after junctional assembly was 214 
initiated, the cells with E-cadherin, LKB1 or AMPK inhibited had only modest (but 215 
statistically significant) alterations in their barriers (Fig.  5d). Interestingly, a slight 216 
alteration in barrier function at 24h after calcium readdition was observed in the MCDKII 217 
cells lacking E-cadherin. The requirement for AMPK is in good agreement with previous 218 
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studies showing that treatment of epithelial cells with AMPK activators promoted barrier 219 
function34. Taken together, these data indicate force-induced activation of LKB1/AMPK 220 
is required for efficient formation of an epithelial barrier. 221 
 222 
Cell differentiation, proliferation, gene expression and disease development are 223 
all impacted by the forces experienced by the cell35-38.  A vast literature shows that cells 224 
withstand forces by reinforcing their actin cytoskeletons and growing their adhesion 225 
complexes1-3, 26. These events increase enzymatic activity, actin polymerization, and 226 
actomyosin contractility26-28, yet it is unknown how the cell derives the vast amount of 227 
energy it needs to support these events. Here, we demonstrate that LKB1-mediated 228 
activation of AMPK is a key player in a junctional contractility pathway that increases 229 
glucose uptake and ATP synthesis. This is a mechanism for how cells signal to increase 230 
energy and use the energy to reinforce their cytoskeletal networks in order to resist 231 
applied forces.  232 
 233 
This work establishes AMPK as a critical link between mechanotransduction and 234 
metabolism. This information may serve as the impetus for future studies aimed at 235 
establishing further links between mechanotransduction and the metabolic machinery 236 
and defining mechanisms of regulation. This work also has the potential to have far 237 
reaching medical implications as AMPK is a negative regulator of diseased states with 238 
metabolic disturbances. Our observation that E-cadherin force transmission activates 239 
AMPK demonstrates that mechanical forces on E-cadherin may protect against the 240 
metabolic disturbances associated with diseases such as cardiovascular disease39, 241 
diabetes40, and cancer38.   242 
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Figure Legends. 260 
Figure 1. AMPK is activated in response to force applied to E-cadherin. a and b, MCF10A 261 
cells were incubated with magnetic beads coated with IgG or E-cadherin extracellular domains 262 
(E-cad). The cells were left resting(-) or a magnet was used to generate tensional forces (+). a, 263 
AMPK immunoprecipitates were subjected to in vitro kinase assay with its substrate, SAMS 264 
peptide. SAMA=control peptide. Cmpd. C indicates cells pretreated with the AMPK inhibitor, 265 
Compound C. b, total cell lysates were immunoblotted with antibodies that recognize AMPK or 266 
AMPK phosphorylated in its activation loop (pAMPK). shControl indicates cells treated with 267 
scrambled shRNAs. shAMPK1and shAMPK2 indicate cells infected with two separate shRNAs 268 
targeting AMPK. c, shear stress was applied to MDCK cells, and AMPK and pAMPK were 269 
monitored by immunoblotting. d, tensional forces (+) were applied to MCF10A cells pretreated 270 
with blebbistatin (Blebbi) or E-cadherin function blocking antibodies (HECD-1). Total cell lysates 271 
were probed with antibodies against pAMPK, AMPK, phospho-myosin light chain (pMLC), or 272 
MLC. e, MCF10A cells were left resting (-) or treated (+) with Calyculin A (to stimulate myosin II-273 
dependent increased contractility). Total cell lysates were immunoblotted as described in d. f 274 
and g, Tensional forces were applied to MCF10A cells as described in a. The beads were 275 
recovered and co-precipitation of AMPK (f) and pAMPK (g) with E-cadherin were examined by 276 
immunoblotting. The graphs beneath the image show the average ± SEM for 3 independent 277 
experiments. *, #, and ## indicate p-values of <0.01, 0.05 and 0.005, respectively. Unprocessed 278 
scans of blots are shown in Supplementary Figure 5. 279 
 280 
Figure 2. LKB1 is recruited to the cadherin adhesion complex in response to force and 281 
activates and recruits AMPK. MCF10A cells (a,b,d,g) or MDCK cells (e) were incubated with 282 
beads coated with IgG or E-cadherin extracellular domains (E-cad) and left resting (-) or 283 
stimulated (+) with tensional force using a permanent magnet. In other experiments, MDCK 284 
cells (c and f) were left resting (-) or exposed to shear stress (+). a, the cells were lysed and co-285 
precipitation of LKB1 with the E-cadherin-coated magnetic beads was examined. b, Co-286 
immunoprecipitation of E-cadherin (E-cad) with LKB1 was monitored using immunoblotting. c, 287 
The cells were fixed, permeabilized and stained with antibodies against E-cadherin or LKB1. 288 
The co-localization of LKB1 with E-cadherin was examined using confocal microscopy. Scale 289 
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bar = 20µm. d-f, The cells were lysed, and whole cell lysates were immunoblotted with the 290 
indicated antibodies.  shLKB1 denotes cells with LKB1 silenced. shLuc indicates cells 291 
expressing a vector control cDNA, and cl.11 and cl.14 indicate two clonal cell lines lacking 292 
LKB1. g, the cells were lysed, and pAMPK and AMPK co-purification with the E-cadherin-coated 293 
magnetic beads was examined by immunoblotting.  The graphs beneath each image show the 294 
average ± SEM for 3 independent experiments.* and # indicate p-values of <0.01, and <0.05, 295 
respectively. Unprocessed scans of blots are shown in Supplementary Figure 5. 296 
 297 
Figure 3. LKB1 and AMPK are upstream of Abl-mediated phosphorylation of Y822 298 
vinculin and Rho-mediated contractility. a, schematic of the signal transduction cascade 299 
from E-cadherin to Rho-mediated contractility. b-h, MCF10a cells were incubated with beads 300 
coated with IgG or E-cadherin extracellular domains (E-cad) and left resting (-) or stimulated (+) 301 
with tensional force using a permanent magnet. b,c,d,e, whole cell lysates were probed by 302 
immunoblotting with antibodies that recognize phosphorylation of CrkL at the Abl-specific site (b 303 
and c, pCrkL) or phosphorylation of vinculin Y822 (d and e, pY822). f, AMPK was 304 
immunoprecipitated and vinculin and Abl recruitment were examined by immunoblotting.  g, 305 
Active Rho (Rho–GTP) was isolated with GST–RBD and analyzed by western blotting.  h, total 306 
cell lysates were immunoblotted with antibodies against myosin light chain  (MLC) or MLC 307 
phosphorylated at Serine 19 (pMLC). shLKB1 denotes cells expressing shRNAs against LKB1. 308 
shControl indicates cells treated with scrambled shRNAs. shAMPK1and shAMPK2 indicate cells 309 
infected with two separate shRNAs targeting AMPK. The graphs beneath each image show the 310 
average ± SEM for 3 independent experiments. **, * and # indicate p-values of <0.001, <0.01, 311 
and 0.05, respectively. Unprocessed scans of blots are shown in Supplementary Figure 5. 312 
 313 
Figure 4. Force-induced AMPK stimulates glucose uptake and increases intracellular ATP 314 
levels. a and b, MCF10A (a) or MDCK (b) cells were incubated paramagnetic beads coated 315 
with IgG or E-cadherin extracellular domains (E-cad). Tensile forces were applied to the beads 316 
using a magnet, the cells were lysed, and the amount of a fluorescently-labelled 2-deoxyglucose 317 
analog taken up into the cells was monitored using a fluorimeter. c, MDCK cells were left resting 318 
(no shear) or exposed to shear stress (shear), and the amount of glucose taken up into the cells 319 
was monitored as described in a. d and e, Total ATP levels in cells treated as described in a 320 
and b were monitored as described in the experimental procedures. Cmpd C indicates cells 321 
treated with the AMPK inhibitor Compound C, Oligo indicates cells treated with the ATP 322 
synthase inhibitor, Oligomycin A, and 2-DG indicates cells incubated in the presence of 2-323 
deoxyglucose. The graphs represent average glucose uptake or intracellular ATP for at least 324 
three representative experiments ± SEM.  # and ## indicate p-values of <0.05 and < 0.005, 325 
respectively. n.s. indicates that there is no statistical differences between groups.  326 
 327 
Figure 5. Force-induced increases in ATP reinforce the actin cytoskeleton and the E-328 
cadherin adhesion complex to modulate barrier formation. a-c, MDCKII cells (n=80) or two 329 
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clonal MDCKII cells lines (cl.11 and cl.14, n=63 and 52 respectively) lacking LKB1 were left 330 
untreated, treated with inhibitors of AMPK (Compound C=Cmpd. C, n=62) or ATP synthesis 331 
(Oligo A,n=44 or Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone=FCCP, n=26, or 332 
incubated in low glucose containing media (Low Gluc, n=25). The cells were then left resting (no 333 
shear) or exposed to physiological shear stress. The cells were fixed, stained with antibodies 334 
against E-cadherin or Texas-Red phalloidin, and examined by confocal microscopy. The graphs 335 
in b and c represent the average corrected fluorescence intensity of E-cadherin (b, E-cad) or F-336 
actin (c) in junctions.The data are represented as a box and whisker plot with median, 10th, 25th, 337 
75th, and 90th percentiles shown. Scale bars=20 μm. d, MDCKII cells were grown to confluence 338 
and then incubated overnight in low calcium containing media. The formation of cell-cell 339 
junctions was then stimulated by adding growth media to the cells. The trans-epithelial 340 
resistance across the epithelial monolayer was monitored using a voltmeter at the indicated 341 
times (hours).  **,*, and # indicate p-values of <0.001, <0.01 and <0.05, respectively. 342 
 343 
 344 
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 1 
Materials and Methods. 2 
 3 
Cell lines.  No cell lines used in this study were found in the database of commonly 4 
misidentified cell lines maintained by the ICLAD and NCBI. MCF10A human breast 5 
epithelial cells and MDCK II canine kidney epithelial cells were purchased from ATCC 6 
and were maintained as previously described11,41.  Cell lines were used for no more 7 
than twelve passages and were tested periodically for mycoplasma contamination 8 
(Lonzo MycoAlert). The cell lines were not authenticated. MDCKII lines expressing 9 
control shLuc, shLKB1 clones 11 and 14, and shE-cadherin were generous gifts from 10 
Dr. Michael Sebbagh17. MDCKII cells were maintained in DMEM (4g/L D-glucose with L-11 
Glutamine) with 10% FBS (Atlanta Biologicals) and 1x Penicillin/ Streptomycin (Sigma). 12 
These lines were chosen for they are both non-tumorigenic epithelial lines that form 13 
strong cell-cell adhesions which have been characterized by our laboratory and 14 
others11,41-43. 293GPG cells are a virus-producing cell line that are a derivative of 293T 15 
cells and were maintained as described previously11. 16 
 17 
Constructs. shRNA lentiviral particles targeting LKB1 and AMPK were purchased from 18 
Santa Cruz (270074-V labeled shLKB1, 29673-V denoted shAMPK1, and 45312-V 19 
termed shAMPK2). Additional control shRNA lentiviral particles containing scrambled 20 
AMPK targeting regions were purchased from Santa Cruz (108080, referred to as 21 
shControl). pLEGFP-vinculin Y822F was generated using site-specific mutagenesis of 22 
pLEGFP-WTvinculin11,42.pGEX4T1-SAMS (aattccacatgaggtccgccatgtccggcttgcacctagtaaaac 23 
gacgac) and SAMA (aattccacatgaggtccgccatggccggcttgcacctagtaaaacgacgac) were 24 
generated by annealing oligonucleotides and ligating oligonucleotides into pGEX4T1 25 
vector (GE Healthcare) cut at Xho1 and EcoR1 restriction sites. pGEX-RBD was a 26 
generous gift from Dr. Keith Burridge (University of North Carolina). 27 
 28 
Magnetic Bead Force Assays. The application of tensile force to E-cadherin using 29 
magnetic beads was performed as previously described11. In brief, paramagnetic beads 30 
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were coated with Fc-Ecadherin, IgG or syndecan-1 antibodies. For the E-cadherin and 31 
IgG coated beads, 1.5 mg Dynabeads Protein A (Invitrogen) were coated with 10 µg 32 
purified Fc-E-cadherin44 or IgG. For the syndecan experiments, 0.75 µg protein G 33 
Dynabeads (Invitrogen) were coated with 10µg syndecan-1 antibody (281.2; BD 34 
Biosciences). The beads were incubated with cells for 40 min at 37°C in the presence or 35 
absence of Compound C (10µM, Sigma), Blebbistatin (50µM, Sigma), or HECD-1 36 
(200µg/mL, Invitrogen). Tensile forces were applied to beads 5-10 minutes using a 37 
permanent ceramic magnet. For all experiments, the magnet was placed parallel to and 38 
at a distance of 0.6 cm from the cell surface, so that the force on a single bead was 39 
approximately 10 pN6,11. After application of force, the cells were transferred to ice and 40 
immediately lysed. 41 
 42 
Shear stress. To examine the cellular response to shear stress, cells were grown to 90-43 
95% confluence on 35mm coverslips coated with 10µg/ml fibronectin. Cells were placed 44 
in a parallel plate flow chamber (Glycotech) and a Buchler polystatic pump was 45 
employed to apply force at 10dyn/cm2 by administering media onto the cells at a rate of 46 
3mL/minute. To determine force, the equation τ =6µQ/a2b 45 was used. τ = shear stress, 47 
dynes/cm2, µ= apparent viscosity of the media (DMEM-F12= 0.009598 Poise or 48 
dynes*sec/ cm2), Q= volumetric flow rate (3 mL/min), a= channel height (0.12 cm), and 49 
b= channel width (2 cm). For signaling and cytoskeletal reinforcement studies, fluid was 50 
passed along the monolayer of cells for 6 hours in the presence or absence of 51 
Compound C (Sigma, 10µM), Oligomycin A (Tocris, 10µM), or Carbonyl cyanide-4-52 
(trifluoromethoxy)phenylhydrazone (i.e. FCCP, Sigma, 1µM) or in low glucose media 53 
(0.5 g/L D-Glucose in DMEM). Cells were then immediately lysed in 2X Laemmli sample 54 
buffer or fixed in 4% paraformaldehyde. For glucose uptake assays, cells were exposed 55 
to shear stress for 2 hours and then allowed to recover for 1 hour with glucose 56 
derivative (2-NBDG).  57 
 58 
Calyculin A Treatment. Cells were grown to near confluence and treated with 5nM of 59 
Calyculin A (Cell Signaling) for 40 minutes and then lysed.  60 
 61 
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Calcium-switch assays. The calcium-switch assays were performed by incubating 62 
cells in calcium-free media for 12 hours and then restoring calcium-containing media for 63 
the times indicated.  64 
 65 
AMPK in vitro kinase assay.  Cells with and without force applied were lysed into an in 66 
vitro kinase assay buffer (50 mM Tris, pH 7.4, 50 mM NaF, 5 mM Na pyrophosphate, 1 67 
mM EDTA, 1 mM EGTA, 250 mM mannitol, 1% (v/v) Triton X-100, 1 mM DTT). AMPK 68 
was immunoprecipitated from whole cell lysates a 1:100 dilution of a polyclonal antibody 69 
against AMPK (2532), and the immunoprecipitates were washed with 50 mM Tris, pH 70 
7.4, 150 mM NaCl, 50 mM NaF, 5 mM Na pyrophosphate, 1 mM EDTA, 1 mM EGTA. 71 
GST-SAMS and GST-SAMA fusion proteins were purified according to the 72 
manufacturer’s instructions. After elution, proteins were concentrated using the Amicon 73 
Ultra 3,000 MWCO system (Millipore). 1 µg of purified SAMS and SAMA proteins were 74 
added to a kinase reaction mixture (1X Hepes- Brif buffer, 250 mM Na Hepes, pH 7.4, 5 75 
mM DTT, 0.1%% Brij-35, 100 µM cold ATP, 300 µM AMP, 25 mM MgCl2, and 10 µCi 76 
32P-ATP). 20µL of the reaction mixture was next added to 5µL of washed protein A 77 
beads with bound AMPK. The reactions were incubated for 30 minutes at room 78 
temperature and stopped by adding 5X Laemmli sample buffer. The samples were 79 
boiled, analyzed by SDS-PAGE, and detected by autoradiography. 80 
 81 
AMPK activator.  Cells without force applied were treated with 100 µM of A-769662 82 
(Selleck Chemical) which is a potent, reversible allosteric activator of AMPK.  Cells were 83 
treated with the activator for 2 hours and then fixed and stained for 84 
immunofluorescence.  85 
 86 
Immunoprecipitation. To immunoprecipitate E-cadherin or LKB1, cells were 87 
solubilized in Extraction Buffer (10 mM Tris-HCl, pH 7.6, 50 mM NaCl, 1% triton X-100, 88 
5mM EDTA, 50 mM NaF, 20 µg/ml aprotinin, 2 mM Na3VO4, and 1 mM PMSF). Clarified 89 
cell lysates were incubated with 6 μg of E-cadherin (HECD-1, Invitrogen) or a 1:100 90 
dilution of a polyclonal LKB1 (Cell Signaling 27D10) antibody, and the resulting antibody 91 
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complexes were recovered with Protein G or Protein A agarose (Sigma). To 92 
immunoprecipitate AMPK, cells were lysed in ice-cold RIPA buffer (50 mM Tris-HCl, pH 93 
7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCI, 2mM EDTA, 50mM 94 
NaF, 20 µg/ml aprotinin, 2 mM Na3VO4, and 1 mM PMSF). Clarified lysates were 95 
incubated with a 1:100 dilution of a polyclonal antibody against AMPK (Cell Signaling 96 
2532). The complexes were recovered with Protein A agarose (Sigma).  97 
 98 
Pulldown assays. Force was applied to cells using the magnetic bead approach 99 
described above with the exception that cells were pretreated for 2 hours with 50µM 100 
blebbistatin (Sigma) or 200µg/mL HECD-1 (Invitrogen). Cells were lysed in ice-cold lysis 101 
buffer (20 mM Tris at pH 7.6, 150 mM NaCl, 0.1% NP-40, 2 mM MgCl2, 102 
20 μg/ ml aprotinin). Cadherin-coated beads were isolated from the lysate using a 103 
magnet and washed three times with lysis buffer. The bound proteins were denatured 104 
and reduced in 2X Laemmli sample buffer and separated using SDS-PAGE. 105 
 106 
RhoA assays. Active RhoA (RhoA-GTP) was isolated using a GST fusion protein with 107 
Rhotekin binding domain (GST-RBD) as detailed in Arthur and Burridge46. The GST-108 
RBD domain binds specifically to GTP-bound, but not GDP-bound, RhoA proteins47. 109 
Cells were lysed in 50 mM Tris (pH 7.6), 500mM NaCl, 0.1% SDS, 0.5% DOC, 1% triton 110 
X-100, MgCl2 and rotated for 30 minutes with 30 μg of purified GST–RBD bound to 111 
glutathione-Sepharose beads. The beads were washed in 50 mM Tris (pH 7.6), 150 mM 112 
NaCl, 1% Triton X-100, 10 mM MgCl2 and the bound proteins were separated using 113 
SDS–PAGE.  114 
Immunoblotting.   Cell lysates were fractionated by SDS-PAGE and transferred to 115 
PVDF (Immobilon). The membranes were blocked in 5% milk (vinculin, E-cadherin), 5% 116 
BSA (AMPK, pAMPK, ACC, pACC) or 1% BSA (pVinculin, pCrkL, CrkL, MLC, pMLC, 117 
Abl) and subjected to Western blot analysis. AMPK was recognized using a polyclonal 118 
antibody from Cell Signaling (2532) that detects both the endogenous α-1 and α-2 119 
isoforms of the catalytic subunit, but not the regulatory γ and β subunits. Phospho-120 
AMPK was detected with an antibody that recognizes AMPK phosphorylated at Thr172 121 
(Cell Signaling Technology, 40H9 2535 @ 1:1000 dilution). LKB1 was recognized with a 122 
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polyclonal antibody from Cell Signaling (27D10 @ 1:1000 dilution). ACC was 123 
recognized with a polyclonal antibody from Cell Signaling (C83B10 @ 1:1000 dilution); 124 
phospho-ACC was detected with an antibody that recognizes ACC phosphorylated at 125 
S79 (Cell Signaling Technology, D7D11@ 1:1000 dilution). Abl kinase was recognized 126 
using a polyclonal antibody raised against a peptide mapping the kinase domain from 127 
Santa Cruz (clone K-12, @ 1:250 dilution). E-Cadherin was immunoblotted with an 128 
HECD-1 mouse monoclonal antibody (Invitrogen 13-1700 @ 1:1000 dilution) or 129 
monoclonal antibody from (BD Transduction Labs @ 1:1000 dilution). Vinculin was 130 
detected with a monoclonal vinculin antibody (hVIN-1, Sigma @ 1:1000 dilution), and 131 
phosphorylated vinculin at Y822 was recognized with a rabbit polyclonal antibody 132 
(AB61071, Abcam @ 1:1000 dilution). CrkL was recognized with a polyclonal antibody 133 
raised against the C-terminus of human CrkL (C-20, Santa Cruz Biotechnology @ 1:250 134 
dilution) and phospho-CrkL was immunoblotted with a polyclonal antibody that 135 
recognizes CrkL phosphorylated at Y207 (3181S, Cell Signaling Technology @ 1:1000 136 
dilution). Phosphorylated myosin light chain (MLC) was detected with antibodies against 137 
phosphorylated serine 19 (3671, Cell Signaling @ 1:1000 dilution). MLC was also 138 
recognized with an antibody from Cell Signaling Technology (3672 @ 1:1000 dilution). 139 
The blots were visualized using chemoluminescence detection reagents (Pierce), and 140 
the signal was detected on x-ray film (Kodak) or a GE Image Quant LAS 400 Imager. 141 
Immunoblots were quantified using the ImageJ program, which measures the integrated 142 
density of bands corrected for background. Shown is the average ratio density from at 143 
least 3 experiments ± standard error of mean. A series of two-tailed student t-tests, 144 
heteroscedastic variance, normal distribution, were performed to determine statistical 145 
significance.   146 
 147 
Immunofluorescence. Cells were fixed in 4% paraformaldehyde in phosphate buffered 148 
saline (PBS), permeabilized in 0.5% Triton X-100 in Universal buffer (UB) (150 mM 149 
NaCl, 50 mM Tris pH 7.6, 0.01% NaN3) for 3 minutes, and washed in UB or PBS.  Cells 150 
were blocked with 5% goat serum in UB for an hour at 37°C, incubated with a primary 151 
antibody for 1 hour at 37°C, washed with UB, and then incubated with secondary 152 
antibody for 1 hour at 37°C.  F-actin was stained using phalloidin conjugated with Texas 153 
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Red at a 1:200 dilution (Life Technologies). E-cadherin was visualized by staining with 154 
HECD-1 (Invitrogen) at a 1:500 dilution, followed by FITC-conjugated goat anti-mouse 155 
IgG (H+L) (Jackson ImmunoResearch Laboratories, Inc) at a 1:500 dilution. To examine 156 
LKB1, cells were blocked in 1% BSA in UB and stained with LKB1 at 1:400 (Cell 157 
Signaling, 27D10). To examine vinculin, cells were blocked with 10% BSA in UB and 158 
stained with hVin-1(Sigma) and F79 (Millipore) at a 1:100 dilution and β-catenin (Sigma) 159 
at 1:750, was and incubated with Texas Red–conjugated donkey anti-rabbit IgG (H + L) 160 
at a 1:500 dilution (Jackson ImmunoResearch Laboratories, Inc.) and FITC–conjugated 161 
donkey anti-mouse IgG (H + L) at a 1:300 dilution (Jackson ImmunoResearch 162 
Laboratories, Inc.). Fluorescence images were captured at room temperature with a 163 
confocal microscope (model LSM 510; Carl Zeiss Micro Imaging, Inc.). We used a 63X 164 
objective (Carl Zeiss Micro Imaging, Inc.) with an NA of 1.2. Images were obtained 165 
using the LSM Image Browser (Carl Zeiss Micro Imaging, Inc.). To examine vinculin the 166 
Leica SP8 confocal microscope was used with a 40X objective. Quantifications of 167 
images were made using ImageJ. Fifty junctions were chosen at random measured at 168 
random over at least five fields of view. Data analyzer was blinded to image identity. A 169 
Dixon Q-test95% was used to determine if data should be excluded. Graphs report the 170 
corrected fluorescence intensity of the regions of interest of interest. The corrected 171 
fluorescence intensity= integrated density- background (area of measurement times the 172 
mean intensity). Data represented as a box and whisker box with 90-10 percentile 173 
shown. Fold increase in intensity was calculated from the average corrected 174 
fluorescence intensity divided by the corrected fluorescence intensity from the untreated 175 
samples and is depicted as the average of 3 independent experiments.  176 
 177 
Glucose uptake assays. Glucose uptake was measured using a kit from Cayman 178 
Chemical (600470). To determine uptake in response to tensile forces, 1.0x105 179 
cells/well were plated in 24-well plates and grown for two days. One hour prior to assay, 180 
cells were transferred to PBS with and without Compound C (10 µM, Sigma) or 181 
200µg/mL HECD-1 (Invitrogen).  50 µg of Dynabeads Protein A (Invitrogen) coated in 182 
0.4 µg Fc-E-cadherin or IgG were incubated with cells for 45 minutes at 37°C. Just prior 183 
to applying force on cells, 33 µg of glucose derivative (2-NBDG) was added to each 184 
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well. Force was applied to beads for 10 minutes, and then the cells were permitted to 185 
recover for 10 minutes at 37°C and lysed in 250µL of 10 mM Tris (pH 7.4), 50mM NaCl, 186 
5mM EDTA, 50mM NaF, 1% triton X-100 and protease inhibitors. The lysate were 187 
centrifuged at 12,000 rpm for 5 minutes at 4 °C, and the resulting supernatant (200µL) 188 
was collected. An equal volume of Cell- Based Assay Buffer (Cayman Chemical, 189 
10009322) was added to the collected supernatant. 100 µL of resulting solution were 190 
loaded into a 96-well plate in triplicate, and a fluorescence reading at 485/535 nm was 191 
taken (Biotek Synergy Neo model NEOALHPA B, Gen 5 software). To evaluate uptake 192 
in response to junction formation, 1.0x105 cells/well were plated in 24-well plates and 193 
grown for 48 hours in calcium-containing media. After 48 hours, the cells were 194 
incubated in calcium-free media for 12 hours and calcium was restored for the times 195 
indicated. The cells were lysed and the amount of glucose uptake was measured as 196 
described above. The glucose uptake concentration was determined using a standard 197 
curve. Results are reported as µg/mL/1x105 cells.    198 
 199 
ATP assays. Cells were plated at a density of 0.75 x105 for 2 days in 35mm dishes. An 200 
hour before applying force, cells were treated with Compound C (Sigma 10µM), 201 
Oligomycin A (Tocris, 10µM), 2-NBDG (fluorescently-labeled 2-deoxyglucose from 202 
Cayman Chemical, 150µg/mL). Dynabeads (0.15mg) coated with 1µg of Fc-E-cadherin 203 
or IgG were incubated with the cells for 45 minutes. Force was applied using a ceramic 204 
magnet for 10 minutes. Intracellular ATP levels were examined using a Fluorometric 205 
ATP assay kit from Abcam (ab83355). Cells were lysed in 200µL of ATP Assay Buffer, 206 
centrifuged at 12,000 rpm for 5 minutes at 4°C, and protein was removed from the 207 
supernatant using a 10 Kd spin column (Thermo Scientific). 5µL of the de-proteinated 208 
sample were added to ATP reaction mix in 96-well plates and a fluorescence reading at 209 
535/587nm was made (Biotek Synergy Neo model NEOALHPA B, Gen 5 software).  210 
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Transepithelial electrical resistance. Cells were plated on Costar® 0.4 µm 211 
Polycarbonate membrane Transwell® 24-well plates and grown to confluence. The cells 212 
were then incubated in calcium free DMEM overnight.  Growth media was added back 213 
to the cultures for the indicated times and transepithelial electrical resistance was 214 
measured in triplicate using a Millipore Voltmeter (MERS 000 01). Results are in Ω*cm2. 215 
 216 
Statistics and Reproducibility. Statistical differences between groups of data were 217 
analyzed using a series of two-tailed unpaired Student t-tests. All experiments were 218 
completed at least three independent times. Key findings were repeated by at least two 219 
of the authors.  220 
Data availability.  All data supporting the findings of this study are available from the 221 
corresponding author on reasonable request. 222 
 223 
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Legends to Supplementary Information 1 
Supplementary Figure 1. The force-induced activation of AMPK occurs in multiple 2 
epithelial cell lines and requires E-cadherin and force transmission. MDCK II (a,e) 3 
or MCF10A (b,c,f,g) cells were incubated with magnetic beads coated with IgG (as a 4 
control), a syndecan-1 antibody, or E-cadherin extracellular domains (E-Cad). The cells 5 
were then left resting (-) or tensile forces were applied to the beads (+), the cells were 6 
lysed, and total cell lysates were immunoblotted with antibodies that recognize AMPK 7 
(a,b,d,e,f), pAMPK(a,b,d,e,f), acetyl CoA carboxylase (c,ACC), acetyl CoA carboxylase 8 
phosphorylated at its AMPK specific site (c, pACC), or E-cadherin (e, E-cad). shE-cad 9 
indicates cells with E-cadherin silenced. shAMPK indicates cells with E-cadherin 10 
silenced. Compound C (Cmpd. C), Blebbistatin (Blebbi) and HECD-1 indicate cells 11 
pretreated with these reagents. d and h, the assembly of cell-cell junctions was 12 
stimulated using a calcium switch assay, and the cells were lysed. The levels of pAMPK 13 
and AMPK were examined by immunoblotting (d) or E-cadherin was 14 
immunoprecipitated and AMPK association was monitored by immunoblotting (h). ’ 15 
indicates minutes after Ca2+ re-addition. Steady indicates cells maintained in growth 16 
media. The graphs beneath the image show the average ± SEM for 3 independent 17 
experiments. **, *, and #  indicate p values of <0.001, <0.01, and <0.05 , respectively. 18 
n.s. indicates not significant. Unprocessed scans of blots are shown in Supplementary 19 
Figure 5. 20 
 21 
Supplementary Figure 2.  LKB1 and AMPK are upstream of Abl-mediated 22 
phosphorylation of Y822 vinculin and RhoA contractility. MDCK II(a) or MCF10A(b-23 
e) cells were incubated with magnetic beads coated with IgG (as a control) or E-24 
cadherin extracellular domains (E-Cad). The cells were left resting (-) or tensile forces 25 
were applied to the beads (+), and the cells were lysed. a  and b, immunoblots of whole 26 
cell lysates showing phosphorylation of CrkL at the Abl-specific site (pCrkL). shLKB1 27 
denotes cells with LKB1 silenced. shLuc indicates cells expressing a control vector 28 
cDNA, and cl.11 and cl.14 indicate two different clonal cell lines lacking LKB1. c, 29 
immunoblots of whole cell lysates showing phosphorylation of vinculin Y822 (pY822). d, 30 
Active Rho (Rho–GTP) was isolated from whole cell lysates with GST–RBD and 31 
analyzed by western blotting. Compound C (Cmpd. C) indicates cells pretreated with 32 
this AMPK inhibitor. Y822F indicates MCF10A cells expressing a mutant vinculin 33 
containing a Y822F vinculin in place of the endogenous protein. e, immunoblots of 34 
whole cell lysates showing myosin light chain (MLC), or MLC phosphorylated in its 35 
regulatory chain (pMLC). The graphs beneath each image represent an average of 36 
three experiments ± SEM. **, *, # and ## indicate p values of <0.001, <0.01, < 0.05 and 37 
<0.005, respectively. n.s. indicates not significant.  Unprocessed scans of blots are 38 
shown in Supplementary Figure 5. 39 
 40 
Supplementary Figure 3. Average fold activation of the glucose uptake and ATP 41 
values. Bar graphs displaying the average fold activation of force-induced glucose 42 
uptake assays (a-d) or of the intracellular ATP levels (e and f) are shown. a-c, The fold 43 
activations for the data presented in Figures 4a-c are shown in panels S3a, S3b, and 44 
S3c, respectively.  d, the amount of glucose taken up into MCF10A cells after a calcium 45 
switch assay performed as described in supplemental Figure 1f. e and f, The fold 46 
activation for ATP levels presented in Figures 4d and e are shown in panels S3e and 47 
S3f, respectively. The values represent the average fold activation from three 48 
independent experiments ± the standard error of the mean.  49 
 50 
Supplementary Figure 4. Controls for shear stress studies in Figure 5. a-h, MDCK 51 
II cells (n=79) or two clonal MDCK II cells lines (cl.11 and cl.14, n=51 and 76 52 
respectively) lacking LKB1 were left untreated, treated with inhibitors of AMPK 53 
(Compound C=Cmpd. C, n=55), treated with inhibitors of ATP synthesis (Oligo A,n=53 54 
or Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone =FCCP,n=29), treated with 55 
inhibitors of myosin II (blebbistatin=Blebbi, n=30), treated with the AMPK activator (A-56 
769662), or incubated in low glucose containing media (Low Gluc, n=25). The cells 57 
were left resting (no shear) or exposed to shear stress (shear). a-d, The cells were 58 
fixed, stained with antibodies against E-cadherin or with Texas-Red labelled phalloidin, 59 
and visualized using confocal microscopy. Representative images are shown in a and d. 60 
Scale bars=20 μm. The graph in b and c represent the average corrected fluorescence 61 
intensity of E-cadherin (b, E-cad) or F-actin (c) in junctions. The data are represented as 62 
a box and whisker plot with median, 10th, 25th, 75th, and 90th percentiles shown. e, the 63 
cells were fixed, stained with antibodies against vinculin or β-catenin, and examined by 64 
confocal microscopy. The graphs represent the average corrected fluorescence 65 
intensity of vinculin (f) or β-catenin (g) in junctions. h, the cells were lysed and total cell 66 
lysates were immunoblotted with antibodies against myosin light chain  (MLC) or MLC 67 
phosphorylated at Serine 19 (pMLC). The graphs beneath each image represent an 68 
average of three experiments ± SEM. **, * and # indicate p values of <0.001, <0.01 and 69 
< 0.05, respectively. n.s. indicates not significant.  Unprocessed scans of blots are 70 
shown in Supplementary Figure 5. 71 
 72 
 73 
Supplementary Figure 5. Uncropped blots from Figures 1, 2, 3 and Supplementary 74 
figures 1, 2 and 4. 75 
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